NEW YORK (TheStreet) -- Arrowhead Research  (ARWR - Get Report) surged Tuesday after Roche's $8.3 billion acquisition of InterMune  (ITMN) led the biotech sector higher.

Roche will pay $74 a share for InterMune, which represents a 38% premium to Friday's closing price of $53.80, in an all-cash deal. The acquisition pushed multiple biotech stocks higher Monday and that upward momentum continued Tuesday.

Deutsche Bank's Robyn Karnauskas told CNBC's Fast Money on Monday that Arrowhead is a takeout target with 100% upside in the next six months.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Arrowhead was up 15.25% to $15.49 at 2:23 p.m. More than 6.8 million shares had changed hands, compared to the average volume of 2,709,760.

ARWR Chart ARWR data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.